RxDoctor Payments Data

Edith McGuire

Family · Farmington, NMNPI 1376105817

Payments from drug & device makers

$567in general payments, 2019–2025

Across 18 payments — averaging $31.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$277
  • Lilly USA, LLC$81
  • Otsuka America Pharmaceutical, Inc.$34
  • Pfizer$34
  • AbbVie$33
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$30
  • plus $79 from 5 others

What the payments were for

  • Food & beverage$567100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$567 in reported general payments places this provider in the 65th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$1,413
Medicare patients
68
Services billed
131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate54$80,828
JardianceEmpagliflozin47$73,507
OzempicSemaglutide52$66,505
TradjentaLinagliptin51$62,264
XifaxanRifaximin15$56,636
TrulicityDulaglutide32$55,760
EliquisApixaban36$54,312
Atrovent HfaIpratropium Bromide74$42,217
FarxigaDapagliflozin Propanediol25$34,919
Lantus SolostarInsulin Glargine,hum.Rec.Anlog189$33,999
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog55$32,147
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$15,577
Combivent RespimatIpratropium/Albuterol Sulfate17$12,982
Fiasp FlextouchInsulin Aspart (Niacinamide)16$12,625
Serevent DiskusSalmeterol Xinafoate27$11,625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$81$55,76032 claims
PfizerEliquis$34$54,31236 claims
GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta$277$31,31553 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,080 family providers in New Mexico.

Other family in Farmington

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →